Last reviewed · How we verify
NCT04279444
Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients
NA trial testing BKR-017 in Type 2 Diabetes in 14 participants. Completed in 15 November 2020.
10 November 2020
Quick facts
| Lead sponsor | BioKier Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 14 |
| Start date | 16 June 2020 |
| Primary completion | 10 November 2020 |
| Estimated completion | 15 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- BKR-017 — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
BioKier Inc. — full company profile →
Who can join
Adults 18 to 70, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect of BKR-017 on insulin resistance in type 2 diabetes (T2D) subjects during 28 days of active test product administration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04279444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BKR-017
Trials testing the same drug.
- NCT06556745 — Pharmacokinetics of Butyrate Tablet BKR-017 · completed
- NCT03999853 — Butyrate Adjuvant Therapy for Type 1 Diabetes · Phase 1, PHASE2 · completed
- NCT04673656 — Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Dia · NA · completed
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other BioKier Inc. trials
Trials by the same sponsor.
- NCT06556745 — Pharmacokinetics of Butyrate Tablet BKR-017 · completed
- NCT04673656 — Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Dia · NA · completed
- NCT03382015 — Effect of BKR-013 on Average Daily Glucose Levels · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04279444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioKier Inc.
- Last refreshed: 4 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04279444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing